

3RD INTERNATIONAL

VEAS

WORKSHOP

September
24-25, 2026

• San Raffaele
Scientific Institute
Milan, Italy



UniSR
Università Vita-Salute
San Raffaele



I.R.C.C.S. Ospedale
San Raffaele
Gruppo San Donato

3RD INTERNATIONAL VEXAS WORKSHOP

Milan, September 24-25, 2026

Following the success of the previous meetings in Paris (2024) and New York (2025), we are delighted to announce that the 3rd International VEXAS Workshop will take place in Milan, September 24-25, 2026.

Building on the strong momentum of these earlier editions, which fostered global collaboration and deepened understanding of this newly defined autoinflammatory condition, the Milan workshop will further expand the international dialogue on VEXAS syndrome.

In 2026, we will once again bring together leading clinicians, researchers, geneticists, biologists, and specialists across hematology, rheumatology, immunology, and disease modelling to explore the rapidly evolving landscape of VEXAS syndrome. The VEXAS Workshop will highlight advances in genetics, clinical spectrum, and therapeutic strategies, with a particular emphasis on integrating emerging scientific insights into pathological mechanism, patient care, and disease management.

A dynamic scientific programme will include interactive case-based sessions, keynote lectures, and multidisciplinary panels designed to connect discovery with patient care. Participants will have the opportunity to share experience, challenge current paradigms, and define the priorities that will shape future research.

This year, two educational sessions will be included. The aim of this sessions is to provide participants with practical tools to recognize, interpret, monitor, and manage the inflammatory and hematological features of VEXAS syndrome in daily clinical practice. Through case-based discussions, the workshop will support the development of a structured differential diagnostic approach in patients presenting with systemic inflammation and/or unexplained hematologic abnormalities. Emphasis will be placed on critical clinical reasoning and on how to appropriately raise and investigate diagnostic suspicion and monitor disease evolution, including the rational use of laboratory, imaging, and genetic testing to confirm the diagnosis.

Our goal is clear: to make Milan 2026 a pivotal step forward in the collective effort to understand and treat VEXAS syndrome. The 3rd International VEXAS Workshop will be the place where collaboration, insight, and innovation come together to improve patients' lives.

3RD INTERNATIONAL VEXAS WORKSHOP

Milan, September
24-25, 2026

PRESIDENTIAL COMMITTEE:

Prof. Simone Cenci

*Director of Division of Genetics
and Cellular Biology,
San Raffaele Hospital, Milan, Italy*

Prof. Fabio Ciceri

*Head of the Stem Cell
Transplantation & Hematology Unit,
San Raffaele Hospital, Milan, Italy*

Prof. Lorenzo Dagna

*Head of Unit of Immunology,
Rheumatology, Allergy and Rare
Diseases (UniRAR),
San Raffaele Hospital, Milan, Italy*

Prof. Luigi Naldini

*Director of SR-Tiget,
San Raffaele Hospital, Milan, Italy*

SCIENTIFIC COMMITTEE:

*Dr. Gregorio M. Bergonzi
Dr. Corrado Campochiaro
Dr. Elisa Diral
Dr. Samuele Ferrari
Dr. Martina Fiumara
Dr. Raffaella Molteni
Dr. Alessandro Tomelleri*

FACULTY:

Alessio Antropoli,

San Raffaele Hospital, Milan, Italy

Federica Barzaghi,

San Raffaele Hospital, Milan, Italy

David Beck,

NYU Langone, New York, USA

Sara Bindoli,

University of Padua, Italy

Chiara Bonini,

San Raffaele Hospital, Milan, Italy

Maria Giulia Cangi,

San Raffaele Hospital, Milan, Italy

Luca Cantarini,

University of Siena, Italy

Steven Chan,

*Princess Margaret Cancer
Centre UHN, Toronto, Canada*

Thibault Comont,

CHU, Toulouse, France

Francesca Crisafulli,

Spedali Civili, Brescia, Italy

Matteo Giovanni Della Porta,

Humanitas University, Milano, Italy

Raffaella Di Micco,

San Raffaele Hospital, Milan, Italy

Marcela Ferrada,

*VEXAS Global Foundation,
New York, USA*

Pierre Fenaux,

University Paris Cité, France

Jacqueline Ferrari,

Policlinico San Matteo, Pavia, Italy

Martina Fiumara,
San Raffaele Telethon Institute
for Gene Therapy, Milan, Italy

Alejo-Rodriguez Fraticelli,
IRB Barcelona, Spain

Cecilia Garlanda,
Humanitas Research Hospital,
Rozzano, Italy

Sophie Georgin-Lavialle,
Sorbonne University, Paris, France

Saghi Ghaffari,
Mount Sinai Hospital, New York, USA

Alexander Gitlin,
MSKCC, Memorial Sloan
Kettering Cancer Center, USA

Peter Grayson,
National Institutes of Health,
NIAMS, Bethesda – MA, USA

Carmelo Gurnari,
Tor Vergata University, Rome, Italy

Jerome Hadjadj,
Hôpital Saint-Antoine, Paris, France

Mael Heiblig,
Centre Hospitalier Lyon Sud, France

Vincent Jachiet,
Hôpital Saint-Antoine, Paris, France

Yohei Kirino,
Yokohama University, Japan

Matthew Koster,
Mayo Clinic, Rochester – MN, USA

Elisa Laurenti,
Cambridge Stem Cell Institute,
United Kingdom

Carlo Alberto Maronese,
Ospedale Maggiore Policlinico,
Milan, Italy

Marco Matucci-Cernic,
San Raffaele Hospital, Milan, Italy

Arsene Mekinian,
Sorbonne University, Paris, France

Alessandra Mortellaro,
San Raffaele Hospital, Milan, Italy

Francesco Muratore,
Modena and Reggio Emilia University,
Reggio Emilia, Italy

Emmanuelle Passagué,
Columbia Stem Cell Initiative,
New York, USA

Bhavisha Patel,
National Institutes of Health,
Bethesda – MD, USA

Katherine Hibbs Pherson,
Globalanalitica, Great Falls, VA, USA

Maurilio Ponzoni,
San Raffaele Hospital, Milan, Italy

Antonio Maria Risitano,
University of Naples “Federico II”, Italy

Sinisa Savic,
University of Leeds, United Kingdom

Serena Scala,
San Raffaele Hospital, Milan, Italy

Maria Sirenko,
NYU Langone, New York, USA

Katja Sockel,
TU Dresden, Germany

Benjamin Terrier,
Hôpital Cochin, Paris, France

Cristina Tresoldi,
San Raffaele Hospital, Milan, Italy

Mona Trivedi,
Novartis, USA

Luca Vago,
San Raffaele Hospital, Milan, Italy

Achim Werner,
National Institutes of Health,
Bethesda – MA, USA

Jacob Werner Hansen,
University of Copenhagen, Denmark

Neal Young,
National Institutes of Health,
Bethesda – MA, USA

Lin-Pierre Zhao,
Hôpital Saint-Louis, Paris, France

PRELIMINARY SCIENTIFIC PROGRAM

THURSDAY, SEPTEMBER 24th

08.30	Welcome and introduction
09.00	KEYNOTE LECTURE <i>Chairs: F. Ciceri, L. Dagna</i> VEXAS Discovery <i>Peter Grayson</i>
09.30	SESSION 1 - Autoinflammatory diseases - VEXAS and beyond <i>Chairs: M. Sirenko, M. Matucci-Cerinic</i> Clinical manifestations of VEXAS syndrome <i>Sinisa Savic</i> Mechanisms of VEXAS pathogenesis <i>David Beck</i> From systemic inflammation to clonal disease: positioning VEXAS among autoinflammatory disorders <i>Sophie Georgin-Lavialle</i> Dysfunction of innate immune system in VEXAS <i>Benjamin Terrier</i>
10.50	Discussion
11.05	Coffee break
11.25	SESSION 2 - Clonal hematopoiesis - VEXAS and beyond <i>Chairs: M. Fiumara, L. Vago</i> Myeloid Clonal Architecture in VEXAS <i>Maria Sirenko</i> Acquired mutations in Aplastic Anemia <i>Antonio Maria Risitano</i> Inflammation-driven Anemia in Lower Risk myelodysplastic syndromes: mechanistic basis and Clinical Trial Landscape <i>Matteo Giovanni Della Porta</i> Clonal Hematopoiesis and Metabolism: A Bidirectional Relationship <i>Steven Chan</i>
12.40	Discussion
12.50	Lunch

13.40	SESSION 3 - Diagnoses, monitoring and treatment of VEXAS <i>Chairs: P. Grayson, M. Ponzoni</i> Techniques for Molecular Disease Monitoring in VEXAS syndrome <i>Carmelo Gurnari</i> VEXAS diagnosis: when to prefer Sanger and when to choose NGS <i>Maria Giulia Cangi</i> Clone-targeted therapy in VEXAS syndrome: 5-azacitidine vs allogeneic stem cell transplantation <i>Vincent Jachiet & Bhavisha Patel</i> Anti-inflammatory therapy in VEXAS syndrome: IL-6 vs JAK inhibitors <i>Jerome Hadjadj & Yohei Kirino</i>
15.00	Discussion
15.15	Coffee break
15.35	SESSION 4 - Oral presentations <i>Chairs: D. Beck, B. Terrier</i> Best abstracts - basic/translational research
16.05	SESSION 5 - Clinical studies of VEXAS <i>Chairs: C. Campochiaro, E. Diral</i> PAXIS clinical trial <i>Matthew Koster</i> RIVET: A phase 1b/2 study of the dual IRAK 1/4 inhibitor R289 in patients with symptomatic VEXAS syndrome <i>Arsene Mekinian</i> Momelotinib in VEXAS syndrome <i>Mael Heiblig</i> VEX-AZA clinical trial <i>Jacob Werner Hansen</i> VEX-AR clinical trial <i>Mona Trivedi</i>
17.20	Discussion
17.35	Poster Session 1
18.30	Adjourn

08.00	Welcome and introduction
08.15	KEYNOTE LECTURE <i>Chairs: S. Cenci, R. Molteni</i> Hematopoietic stem cell gene therapy <i>Luigi Naldini</i>
08.45	SESSION 1 - Tracing origin, fate, and states across hematopoiesis <i>Chairs: G.M. Bergonzi, S. Ferrari</i> Lineage tracing at single cell resolution <i>Alejo Rodriguez Fraticelli</i> Biological properties and clonality of engineered hematopoietic stem/progenitor cells persisting long-term after gene therapy <i>Serena Scala</i> Evolutionary biology, somatic mutations and clonal hematopoiesis <i>Neal Young</i> Dysfunctional Neutropoiesis in DNMT3A-mutated clonal haematopoiesis <i>Elisa Laurenti</i>
10.05	Discussion
10.20	Coffee break
10.40	SESSION 2 - Oral presentations <i>Chairs: B. Patel, A. Tomelleri</i> Best abstracts - clinical research
11.10	SESSION 3 - Stories from patients and caregivers <i>Chairs: A. Camerini, M. Ferrada, K. Hibbs Pherson</i> VEXAS Foundation - Joe Holman <i>Italian caregiver</i>
11.40	EDUCATIONAL WORKSHOPS VEXAS for rheumatologists <i>(C. Campochiaro, S. Georgin-Lavialle, F. Muratore, C.A. Maronese)</i> VEXAS for hematologists <i>(E. Diral, P. Fenaux, L-P. Zhao, A. Antropoli)</i>
12.20	Lunch & Poster Session 2
13.10	EDUCATIONAL WORKSHOPS VEXAS for rheumatologists <i>(F. Crisafulli, B. Terrier, A. Tomelleri, A. Antropoli)</i> VEXAS for hematologists <i>(G. M. Bergonzi, T. Comont, J. Ferrari, C.A. Maronese)</i>

14.00	SESSION 4 - Cellular stress responses - VEXAS and beyond <i>Chairs: R. Di Micco, S. Scala</i> Stem cell biology and stress responses <i>Emmanuelle Passagué</i> Autophagy and UPR <i>Simone Cenci</i> Lysosomes in reversing hematopoietic stem cell aging <i>Saghi Ghaffari</i> VEXAS and UBA1 Mutations as a Window into Ubiquitin Biology <i>Achim Werner</i>
15.20	Discussion
15.35	Coffee break
15.55	SESSION 5 - Patient registries <i>Chairs: C. Gurnari, C. Tresoldi</i> French registry <i>Arsene Meakinian</i> Patient registry <i>Marcela Ferrada</i> German registry <i>Katja Sockel</i> Japanese registry <i>Yohei Kirino</i> AIDA Network VEXAS registry <i>Luca Cantarini</i>
16.45	Discussion
16.55	SESSION 6 - Inflammation and immunity - VEXAS and beyond <i>Chairs: C. Bonini, E. Laurenti</i> Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome <i>Alexander Gitlin</i> IL-1 negative regulation in inflammatory hematopoiesis <i>Cecilia Garlanda</i> DADA2 from basic to translational and clinical research <i>Alessandra Mortellaro & Federica Barzaghi</i> CAR-T mediated selective eradication of senescent cells to treat clonal hematological neoplasms <i>Raffaella Di Micco</i>
18.15	Discussion
18.30	Final remarks

GENERAL INFORMATION

VENUE

San Raffaele Congress Center
Via Olgettina, 58 - Milan, Italy

CALL FOR ABSTRACT

All participants are encouraged to submit an abstract.

Preclinical, translational, and clinical abstracts, including case reports are welcome. Abstract could be selected for oral or poster presentation based on final scoring and ranking.

Notifications will be sent to the presenting author.

Abstract submission deadline:
June 30, 2026

- Abstracts must be submitted in English.
- Abstract title should be max 250 characters (spaces included) and should reflect the content of the abstract.

To submit your abstract please browse www.achelois.eu/events/?anno=2026

The Scientific Committee will make the selection of abstracts for the oral or poster presentation by **July 30, 2026**.

Please note that submitting an abstract does not constitute registration for the meeting. The presenting author of an accepted abstract must register by August 20, 2026. Registration is mandatory.

REGISTRATION FEES

	Early Bird Rate <i>Closing at 23.59 on June 30</i>	Regular Registration <i>From July 1 st</i>
Undergraduate Students	€ 61 VAT included	€ 92 VAT included
PhD Students	€ 61 VAT included	€ 92 VAT included
Residents	€ 61 VAT included	€ 92 VAT included
Clinicians	€ 220 VAT included	€ 280 VAT include
Others <i>(Post-Doctoral fellow/ Instructors/ Group Leaders/ Others)</i>	€ 220 VAT included	€ 280 VAT included
Industry	€ 488 VAT included	€ 549 VAT included

To register, please browse;
www.achelois.eu/events/?anno=2026

AUSPICES



With the auspices of *SIE – Società Italiana di Ematologia*

ACKNOWLEDGMENTS

